Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events

NICE technology appraisals [TA210] Published date:

This guidance updates and replaces NICE technology appraisal 90 (published in May 2005).

The review and re-appraisal of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events has resulted in a change in the guidance. Specifically:

  • Treatment with modified-release dipyridamole in combination with aspirin for people who have had an ischaemic stroke is now recommended only if clopidogrel is contraindicated or not tolerated.
  • Treatment with modified-release dipyridamole in combination with aspirin for people who have had an ischaemic stroke or a transient ischaemic attack is no longer limited to 2 years’ duration from the most recent event.
  • Clopidogrel is no longer recommended only for people who are intolerant of aspirin and have had an occlusive vascular event or have peripheral arterial disease.

Modified-release dipyridamole alone is now recommended as an option to prevent occlusive vascular events.

Get involved